Navigation Links
TissueGene Initiates Patient Enrollment for a Phase II Study of TG-C for Osteoarthritis of the Knee
Date:5/19/2011

ROCKVILLE, Md., May 19, 2011 /PRNewswire/ -- TissueGene, Inc. announced today that it has initiated patient enrollment for a U.S. Phase II clinical trial of its lead product candidate TG-C.  TG-C involves human allogeneic chondrocytes developed to produce the therapeutic protein TGF-beta1 for the regeneration of cartilage in patients suffering from severe osteoarthritis of the knee.  

The randomized, double-blind, placebo-controlled Phase II study will evaluate the safety and efficacy of TG-C in patients with chronic degenerative joint disease (DJD) of the knee.  Patients will receive an intra-articular injection of either TG-C or placebo to the damaged joint area with primary and secondary endpoints involving evidence of symptomatic improvement and cartilage regeneration, respectively.  This multi-center study will be conducted at hospitals and clinical research centers across the United States specializing in orthopedic research and is expected to include 100 patients.  In conjunction with these efforts, TissueGene's licensing partner, Kolon Life Science, Inc. (KOSDAQ: 102940) anticipates the initiation of a Phase IIb single-dose study for TG-C in Korea by 3Q 2011, having previously received regulatory allowance by the Korean FDA to proceed. 

"We are pleased to have reached another significant milestone with the start of our U.S. Phase II study of TG-C," stated Dr. Kwan Hee Lee, Chief Medical Officer of TissueGene.  "We believe that TG-C has the potential to become the first noninvasive treatment for osteoarthritis by regenerating cartilage through a simple injection into the knee."  

About TissueGene, Inc.

TissueGene, Inc. is a Maryland-based biopharmaceutical company with a pipeline of noninvasive regenerative medicine therapies in the field of cell therapy. TissueGene's core technology employs a form of cell-mediated therapy to deliver therapeutic proteins to localized areas of damage
'/>"/>

SOURCE TissueGene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Proteon Therapeutics Initiates Patient Enrollment in Phase 2 Clinical Study of PRT-201 in Hemodialysis Patients
2. S*BIO Initiates Phase 2 Clinical Trial of its Novel JAK2 Inhibitor SB1518 in North America for Advanced Lymphoid Malignancies
3. Stephens Initiates Coverage on Vermillion
4. Cell Therapeutics Initiates Pixantrone PIX-R Pivotal Trial for Treatment of Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
5. American Regent Initiates Voluntary Nationwide Recall of Dexamethasone Sodium Phosphate Injection, USP, 4 mg/mL, 1 mL Single Dose Vials; 5 mL and 30 mL Multiple Dose Vials
6. CalciMedica Initiates Phase I Clinical Trial of First CRAC Channel Inhibitor (CCI) for Psoriasis
7. Max Neeman International Initiates Advisory Committee to Advance and Improve the Conduct of Complex Neurological Trials in India
8. Aperion Biologics Initiates Clinical Trial of Z-Lig™ Device for Anterior Cruciate Ligament Reconstruction
9. Research 2.0 Initiates Coverage of Viral Genetics and Publishes Research Report
10. Onyx Pharmaceuticals Receives Fast Track Designation for Carfilzomib; Company Initiates Rolling NDA Submission for Accelerated Approval
11. MacroGenics Initiates Phase I Clinical Trial of MGAH22 for Patients With HER2-Expressing Solid Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... (PRWEB) July 22, 2014 Quorum Review IRB, ... service for large clinical trials called Quick Step™ . ... designed to address the research industry’s need for seamless study ... service is available for studies planning 50 or more North ... combined planned North American site count of 80 or more. ...
(Date:7/22/2014)... SILVER SPRING, Md. , July 22, 2014 ... ) announced today that it will release its ... on Tuesday, July 29, 2014. United ... July 29, 2014, at 9:00 a.m. Eastern Time.  ... international callers dialing 1-970-315-0533.  A rebroadcast of the ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 Holomic ... with the debut of its fluorescent immunoassay reader, ... Chemistry (AACC) meeting in Chicago, July 28-31, 2014. ... top versions, the HRDR-300 is a highly sensitive, ... to analyze fluorescent lateral flow immunoassays with high ...
(Date:7/22/2014)... Juli 2014 Qforma, ein führender Anbieter ... von Marcus Bergler zum General Manager ... europäischen kommerziellen Aktivitäten von Qforma bereits als Vice ... anschloss, war er in Positionen als VP Vertrieb ... Deutschland bei IMS Health und als Direktor bei ...
Breaking Biology Technology:Quorum Review IRB Launches New Quick Step™ Service for Large Clinical Trials 2Quorum Review IRB Launches New Quick Step™ Service for Large Clinical Trials 3Holomic to Debut HRDR-300 Fluorescent Immunoassay Reader at the AACC 2014 2Qforma gibt Schaffung des neuen Postens als General Manager in Europa bekannt 2
... Biotech Inc.,(TSX: ONC, NASDAQ: ONCY) (,Oncolytics,) reported ... group at The Institute of Cancer Research,London, ... characterizing immune,system responses to administration of intravenous ... paper, entitled "Characterization of the Adaptive and,Innate ...
... 17 OmniSonics Medical,Technologies, Inc., a developer of ... vascular disease, announced today that it has enrolled ... SONIC I is a prospective,multi-centered U.S. registry study ... undergoing percutaneous mechanical,thrombectomy of acute deep vein thrombosis ...
... ANGELES, March 17 Signalife, Inc. (Amex:,SGN - ... several formal,purchase and financial commitments with respect to ... These commitments have,come internationally, including in Japan, other ... Dr. Harmison, the Company,s President and CEO, ...
Cached Biology Technology:Oncolytics Biotech Inc. Announces Publication of Research on Immune Response to REOLYSIN(R) during a Phase I Clinical Trial 2First Patient Enrolled in SONIC I Registry of OmniSonics Medical Technologies' OmniWave(TM) Endovascular System 2Signalife Sees Accretive Purchase and Financial Commitments 2
(Date:7/22/2014)... July 22, 2014, Cleveland: A type of immune ... diseases, such as Alzheimer,s disease and multiple sclerosis ... brain injury (TBI) and may slow the progression ... published today in the online journal Nature ... Bruce Trapp, PhD, Chair of the Department of ...
(Date:7/22/2014)... Not much is known about the the genus of ... after a new one was recently discovered in the ... city of Jaen. A description of it appears in ... http://www.insectscience.org/14.92/ ). , The new species, Conosimus ... Spanish hemipterologist, for his contributions to the taxonomy of ...
(Date:7/21/2014)... part of a multinational, collaborative effort, researchers from Canada,s ... identify over 100 locations in the human genome associated ... the largest genomic study published on any psychiatric disorder ... , point to biological mechanisms and pathways that may ... treating the disorder, which has seen little innovation in ...
Breaking Biology News(10 mins):Cleveland Clinic researchers discover neuroprotective role of immune cell 2International team sheds new light on biology underlying schizophrenia 2International team sheds new light on biology underlying schizophrenia 3
... brain assigns cells to participate in encoding and storing memories. ... a protein called CREB controls the odds of a neuron ... edition of Science reports the findings, which suggest a new ... other brain injury. , "Making a memory ...
... 2007, issue of the journal Neuron, published by Cell ... numerical information--both abstract quantities and their concrete representations as ... understanding how the brain processes quantitative information as well ... the brain develops in children. Such studies could aid ...
... protein protects human pancreatic cancer cells from being forced ... defenses against out-of-control cell growth, researchers at The University ... the March issue of Molecular Cancer Research. , The ... has been found by researchers at M. D. Anderson ...
Cached Biology News:UCLA/Toronto researchers unlock key to memory storage in brain 2Studies yield insight into the numerical brain 2Studies yield insight into the numerical brain 3Studies yield insight into the numerical brain 4Protein found to shield pancreatic cancer cells from self-destruction 2
... Clone/PAD: ZMD.257. Immunogen: Synthetic peptide derived ... human Connexin 36 protein This peptide ... to generate another Zymed polyclonal Connexin 36 ... with mouse Connexin 36. Reactivity: Mouse ...
Invitrogen's Calcium Phosphate Transfection Kit provides high-quality reagents to enable the introduction of DNA into tissue culture cells via calcium phosphate co-precipitation....
...
...
Biology Products: